Cocrystal Pharma Inc

COCP

Company Profile

  • Business description

    Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

  • Contact

    19805 North Creek Parkway
    BothellWA98011
    USA

    T: +1 877 262-7123

    E: [email protected]

    https://www.cocrystalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    10

Stocks News & Analysis

stocks

ASX healthcare share undervalued post earnings

Short term headwinds mask long term value opportunity.
stocks

ASX energy share sees 363% increase in dividend

Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,338.8054.50-0.58%
CAC 408,462.3923.190.27%
DAX 4026,285.9619.820.08%
Dow JONES (US)53,511.6665.74-0.12%
FTSE 10010,878.128.04-0.07%
HKSE25,652.97141.870.56%
NASDAQ26,173.4022.100.08%
Nikkei 22566,262.16405.730.62%
NZX 50 Index14,013.2120.490.15%
S&P 5007,688.1110.830.14%
S&P/ASX 2009,127.8055.90-0.61%
SSE Composite Index3,912.5223.080.59%

Market Movers